March 26, 2008
ALLAY is the largest study on regression of left ventricular hypertrophy with MRI technique and included over 400 patients in seven countries from all over the world. ACCOMPLISH is a comparison study of two fixed combination drugs (more below) and included over 11 000 patients in six countries.
ALLAY is the largest study on regression of left ventricular hypertrophy with MRI technique and included over 400 patients in seven countries from all over the world. ACCOMPLISH is a comparison study of two fixed combination drugs (more below) and included over 11 000 patients in six countries.
Background information
ALLAY
ALLAY aimed “to compare the efficacy and safety of aliskiren and aliskiren in combination with losartan to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure” (ClinicalTrials.gov, NCT00219141). ALLAY is the largest study on regression of left ventricular hypertrophy with MRI technique.
A+ Science has contributed to the performance of the ALLAY study with:
- Expertise in study design
- ECG handling and administration
- ECG coding of all ECG (through dedicated core center)
ACCOMPLISH
ACCOMPLISH is “a comparison study of two fixed combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population” (ClinicalTrials.gov, NCT00170950).
A+ Science has contributed to the performance of ACCOMPLISH study with:
- Design and expertise
- Project Management
- Center selection (n=155) in the Nordic countries
- Patient recruitment (n=3353)
- Monitoring of all Nordic centers
- ECG handling and central reading (>30000)
ASCOT
ASCOT was important for the thinking behind both ALLAY and ACCOMPLISH. The ASCOT study was an independent, investigator-led study set up to compare different treatment strategies in the prevention of cardiovascular disease in patients who were hypertensive but were not considered conventionally dyslipidemic. The ASCOT study main results have been published with several articles in The Lancet. Find out more about ASCOT through their website.
In the ASCOT study A+ Science contributed with:
- Idea, design and power-calculation
- Database building (accepted by FDA)
- Center-selection (n=686 in the Nordic countries)
- Recruitment of > 10000 patients
- Coordination and Project Management
- Monitoring
- Endpoint adjudication (>10000 endpoints) and database
- ECG coding, handling and database (> 60000 ECGs)
- MEDRA coding
- Statistical analyses and medical report FDA submission
For more information:
Pirkko Sulila, Senior Vice President Marketing, Sales and Business Development, Tel. +46 8 564 882 42
email pirkko-(d_)-_sulila-(_sm3Remove)-_-(_a)-_a-plusscience-(d_)-_com
Wordlist
ALLAY: Aliskiren in Left Ventricular Hypertrophy
ACCOMPLISH: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension
ASCOT: Anglo Scandinavian Cardiac Outcomes Trial
Return to news list